Last reviewed · How we verify

NCT06882642

Sensory Integration Therapy in a Sample of Children With Autism Spectrum Disorder

Completed NA Last updated 22 May 2025
What this trial tests

NA trial testing Sensory integration therapy in Autism Spectrum Disorder in 30 participants. Completed in 28 March 2025.

Timeline
1 May 2023
Primary endpoint
28 March 2025
28 March 2025

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 May 2023
Primary completion28 March 2025
Estimated completion28 March 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 3 to 10, any sex, with Autism Spectrum Disorder or Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine the effects of therapy in sensory rooms with multisensory environment on the severity of autism spectrum disorder and stereotyped and repetitive behaviours in a sample of Egyptian children with autism spectrum disorder

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sensory integration therapy

Trials testing the same drug.

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06882642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing